News
![Is Regeneron Stock a Buy Now?: https://g.foolcdn.com/editorial/images/745110/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEorYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b0fe4d930734aea0a4031aa5ea5ac65160e7b0c9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=us)
Is Regeneron Stock a Buy Now?
There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea
![Stock Market Sell-Off: 3 Tech Stocks Investors Should Avoid Right Now: https://g.foolcdn.com/editorial/images/745218/person-puts-up-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOU45YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d0a1b1c2aa9968166b77fd61f320b9e4f6852c9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-puts-up-hand.jpg?locale=us)
Stock Market Sell-Off: 3 Tech Stocks Investors Should Avoid Right Now
The stock market seems uncertain right now. Some stocks experienced continued declines even after a massive sell-off in the 2022 bear market. Others recovered significantly in the first half of the
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
![1 Green Flag for AT&T Stock Investors: https://g.foolcdn.com/editorial/images/745365/att-stock-green-flag.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUo5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7c0021666d7be4ebecc00cff153c2cbd04ed53f4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att-stock-green-flag.png?locale=us)
1 Green Flag for AT&T Stock Investors
Fool.com contributor Parkev Tatevosian highlights AT&T's (NYSE: T) financial progress in reducing its debt to lower interest expenses.
*Stock prices used were the afternoon prices of Aug. 22, 2023
![Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris: https://g.foolcdn.com/editorial/images/745296/researcher.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3A5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7aae4cdfeff66f919db6a5986af5d443b0eef438/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/researcher.jpg?locale=us)
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).
Both companies offer
![Why Invitae Stock Is Crashing Today: https://g.foolcdn.com/editorial/images/745324/dna-with-icons-and-doctor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeDk5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3adec0fc5a22bec921ca0e38bec289e8b11bf2fc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-with-icons-and-doctor.jpg?locale=us)
Why Invitae Stock Is Crashing Today
Shares of Invitae (NYSE: NVTA) were crashing 19.4% lower as of 12:13 p.m. ET on Thursday. The decline came on the heels of two developments.
Invitae revealed in a regulatory filing on Wednesday that
![2 No-Brainer Biotech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/744853/a-scientist-working-in-a-lab.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNDk4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--347f2b6c798a73136a7a8a7e9bff4225d7794402/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-scientist-working-in-a-lab.jpg?locale=us)
2 No-Brainer Biotech Stocks to Buy Right Now
Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
![Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?: https://g.foolcdn.com/editorial/images/744779/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTU4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--460e5e156dae3cea0cdc16e6ecf087f772e7c183/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg?locale=us)
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
News from the Food and Drug Administration (FDA) can often make or break a stock. This month, it broke Sage Therapeutics (NASDAQ: SAGE).
Although the company obtained approval for its depression
![AT&T Is Generating Growth in a Stagnant Industry: https://g.foolcdn.com/editorial/images/745235/its-time-to-celebrate.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGg4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e82883339c3cd2821bbd4bcfd36e9c28572671cf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/its-time-to-celebrate.jpg?locale=us)
AT&T Is Generating Growth in a Stagnant Industry
Fool.com contributor Parkev Tatevosian discusses how AT&T (NYSE: T) is managing to add customers and revenue despite operating in a saturated market.
*Stock prices used were the afternoon prices of
![2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now: https://g.foolcdn.com/editorial/images/745168/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1I3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--905c4ff6816ce0350a37f78bf07ef1a01b794b3a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=us)
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
Dividend stocks can be a port in the storm. Thanks to powerful wealth-building vehicles like dividend reinvestment plans, these stocks can take advantage of the power of both dollar-cost averaging
![Is Sarepta Therapeutics Stock a Top Growth Vehicle?: https://g.foolcdn.com/editorial/images/745145/growth.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTE3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfcbea0b6c4ab62ac15e7b6f60f35c9ebf27095a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth.jpg?locale=us)
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
Growth stocks have hit a rough patch lately. The Nasdaq Composite, a benchmark for many growth-oriented companies, has declined by about 5% since the beginning of August, and many individual growth
![Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought: https://g.foolcdn.com/editorial/images/745119/gettyimages-1206327647.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEo3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6ebd31400e4e3ccdfab67eacb82f555a3d16defd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1206327647.jpg?locale=us)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
If Wall Street is having a back-to-school sale, Cathie Wood is shopping. The widely followed growth investor who leads Ark Invest did a fair amount of buying on Tuesday. She publishes her daily
![Could This Medicine Be the Next Winner for Novartis?: https://g.foolcdn.com/editorial/images/744947/a-patient-attends-a-doctor-appointment.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjk3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e905c481e0c2cd257bd4f550754ad4b91e4bffc9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-patient-attends-a-doctor-appointment.jpg?locale=us)
Could This Medicine Be the Next Winner for Novartis?
Earlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug candidate remibrutinib for a skin condition known
![3 Stocks With High Dividend Yields: https://g.foolcdn.com/editorial/images/745096/climbing-coins-beating-inflation-rising-prices.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN043YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7e2ff8e16536d5dcd6537956f0ade50ae5ba9a75/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/climbing-coins-beating-inflation-rising-prices.jpg?locale=us)
3 Stocks With High Dividend Yields
Many companies have put a lower priority on paying dividends over the years. The average dividend yield of stocks in the S&P 500 has fallen from over 3% a few decades ago to less than 2% in the past
![Want Growing Passive Income? This Dividend King Could Be a Smart Buy: https://g.foolcdn.com/editorial/images/744673/a-doctor-and-patient-talk-to-each-other-during-an-appointment.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWw3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5e7527e081bf49959bae8b340d4371640f984adf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-and-patient-talk-to-each-other-during-an-appointment.jpg?locale=us)
Want Growing Passive Income? This Dividend King Could Be a Smart Buy
More than three years after deeming COVID-19 a global health emergency, the World Health Organization ended the pandemic's special status in May.
This was certainly welcome news for numerous
![These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street: https://g.foolcdn.com/editorial/images/744604/doctor-and-patient-in-a-hospital-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMjE3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--69f86b92445d8566c4ced255ce974468420e4ae0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-in-a-hospital-room.jpg?locale=us)
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as
![3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?: https://g.foolcdn.com/editorial/images/744518/female-scientist-observing-with-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeE43YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--063c2a35a1189e5c5af369248b224aa3328873fa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/female-scientist-observing-with-microscope.jpg?locale=us)
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
![5 Smart Reasons to Buy AT&T Stock Right Now: https://g.foolcdn.com/editorial/images/744918/investor-gettyimages-1128873197.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzE2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--da20ae248d4c4f8e3aabd237987a1b5a81af56aa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-gettyimages-1128873197.jpg?locale=us)
5 Smart Reasons to Buy AT&T Stock Right Now
Shares of AT&T (NYSE: T) are trading near multi-decade lows. Bargain hunters are circling and for good reason. Many of the risks the telecom titan faces are arguably already reflected in its
![Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It: https://g.foolcdn.com/editorial/images/744515/investors-considers-papers-on-a-table-while-holding-a-tablet.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzU2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8f56c20ca66ec91b9efeb20e10b66eb0ebf31bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investors-considers-papers-on-a-table-while-holding-a-tablet.jpg?locale=us)
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
If you've invested in biopharma anytime recently, you've probably heard the acronym NASH. It stands for nonalcoholic steatohepatitis, a liver disease characterized by fat accumulating on the liver
![Why Are Shares of Novavax Soaring Today?: https://g.foolcdn.com/editorial/images/745039/vaccine-2023.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2g2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ec692a8f85859a7733136476b8354fffabfbaaf5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vaccine-2023.jpg?locale=us)
Why Are Shares of Novavax Soaring Today?
Investors in Novavax (NASDAQ: NVAX) haven't had much to celebrate recently, but the stock is rocketing higher on Tuesday. As of 11:30 a.m. ET, Novavax shares were up more than 17%, despite the
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
![2 Reasons to Buy AT&T Stock, and 1 Reason to Avoid It: https://g.foolcdn.com/editorial/images/744146/doctor-using-their-phone.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODE1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--abfff478080c2a09731955cd2371ad2549804c25/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-using-their-phone.jpg?locale=us)
2 Reasons to Buy AT&T Stock, and 1 Reason to Avoid It
Every investor has different timelines and goals, and the stocks they select to fill a portfolio should mirror those goals. While some may not care about dividends, others value them highly, even if
![EQS-News: Evotec SE reports first half-year 2023 results on 29 August 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)